A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This literature review assessed the burden of treatment-resistant depression in the United States by compiling published data about the clinical, societal, and economic outcomes associated with failure to respond to one or more adequate trials of drug therapy. METHODS: PubMed and the Tufts Cost-Effectiveness Analyses Registry were searched for English-language articles published between January 1996 and August 2013 that collected primary data about treatment-resistant depression. Two researchers independently assessed study quality and extracted data. RESULTS: Sixty-two articles were included (N=59,462 patients). Patients with treatment-resistant depression had 3.8±2.1 prior depressive episodes and illness duration of 4.4±3.3 years and had completed 4.7±2.7 unsuccessful drug trials involving 2.1±.3 drug classes. Response rates for treatment-resistant depression were 36%±1%. A total of 17%±6% of patients had prior suicide attempts (1.1±.2 attempts per patient). Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response. Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression. CONCLUSIONS: Treatment-resistant depression exacts a substantial toll on patients' quality of life. At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion. These findings underscore the need for research on the mechanisms of depression, new therapeutic targets, existing and new treatment combinations, and tests to improve the efficacy of and adherence to treatments for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant.”
In the citing paper
“Among private payers, the mean annual direct healthcare costs per patient for the management of TRD (US$13,196; 2013 GBP8437) were higher than for management of treatment-responsive depression (US$7715; 2013 GBP4933) 14”
In the citing paper
“These cardiovascular effects may complicate treatment of patients with TRD who, in real-world settings, often have hypertension (67%) and cardiovascular disease (56%) [15].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [15]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Williams, D. R., González, H. M., Neighbors, H., Nesse, R., Abelson, J. M., Sweetman, J., & Jackson, J. S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.305 · Cited by 1,293
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Disparity in Depression Treatment Among Racial and Ethnic Minority Populations in the United States
Alegría, M., Chatterji, P., Wells, K., Cao, Z., Chen, C.-N., Takeuchi, D., Jackson, J., & Meng, X.-L. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.11.1264 · Cited by 993
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Malone, D. A., Dougherty, D. D., Rezai, A. R., Carpenter, L. L., Friehs, G. M., Eskandar, E. N., Rauch, S. L., Rasmussen, S. A., Machado, A. G., Kubu, C. S., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.029 · Cited by 897
Clinical implications of Brief Psychiatric Rating Scale scores
Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.4.366 · Cited by 896
Bewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865
Canadian Journal of Psychiatry
(1979) · The Canadian Journal of Psychiatry · doi:10.1177/070674377902400508 · Cited by 752
(1997) · PubMed · Cited by 727
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 1×
“The designation “treatment resistant” is used to describe patients who do not respond to antidepressant therapy after one or more adequate trials (9–11) (duration of at least six weeks and use of appropriate dosages [12–15]).”
BackgroundPreskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
A Novel Augmentation Strategy for Treating Resistant Major Depression
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.131 · Cited by 504
The British Journal of Medical Psychology
Birtchnell, J., & Crown, S. (1992) · Psychiatric Bulletin · doi:10.1192/s0955603600106580 · Cited by 485
The Burden of Mental Disorders
Eaton, W. W., Martins, S. S., Nestadt, G., Bienvenu, O. J., Clarke, D., & Alexandre, P. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn011 · Cited by 460
(2007) · PubMed · Cited by 453
Bewernick, B. H., Kayser, S., Sturm, V., & Schlaepfer, T. E. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.44 · Cited by 371
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
The mini-mental state examination score and the clinical diagnosis of dementia
Kukull, W. A., Larson, E. B., Teri, L., Bowen, J., McCormick, W., & Pfanschmidt, M. L. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90122-8 · Cited by 313
(2001) · PubMed · Cited by 303
The burden of disease for treatment-resistant depression.
Greden, J. F. (2001) · PubMed · Cited by 279
NIH Disease Funding Levels and Burden of Disease
Gillum, L. A., Gouveia, C., Dorsey, E. R., Pletcher, M., Mathers, C. D., McCulloch, C. E., & Johnston, S. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016837 · Cited by 248
Brent, D. A., Emslie, G. J., Clarke, G. N., Asarnow, J., Spirito, A., Ritz, L., Vitiello, B., Iyengar, S., Birmaher, B., Ryan, N. D., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08070976 · Cited by 235
Transcranial direct current stimulation in severe, drug-resistant major depression
Ferrucci, R., Bortolomasi, M., Vergari, M., Tadini, L., Salvoro, B., Giacopuzzi, M., Barbieri, S., & Priori, A. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.015 · Cited by 228
Hall-Flavin, D. K., Winner, J. G., Allen, J. D., Carhart, J. M., Proctor, B., Snyder, K. A., Drews, M. S., Eisterhold, L. L., Geske, J., & Mrazek, D. A. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283649b9a · Cited by 209
Self-citationUsing a pharmacogenomic algorithm to guide the treatment of depression
Hall-Flavin, D. K., Winner, J. G., Allen, J. D., Jordan, J. J., Nesheim, R. S., Snyder, K. A., Drews, M. S., Eisterhold, L. L., Biernacka, J. M., & Mrazek, D. A. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.99 · Cited by 185
Self-citationRevicki, D. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00117-1 · Cited by 182
Bauer, M., Bschor, T., Kunz, D., Berghöfer, A., Ströhle, A., & Müller-Oerlinghausen, B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1429 · Cited by 176
Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
Health Inequity in Children and Youth With Chronic Health Conditions
Berry, J. G., Bloom, S. R., Foley, S. M., & Palfrey, J. S. (2010) · PEDIATRICS · doi:10.1542/peds.2010-1466d · Cited by 164
Young adults face major barriers to seeking help from mental health services
Vanheusden, K., Mulder, C. L., van der Ende, J., van Lenthe, F. J., Mackenbach, J. P., & Verhulst, F. C. (2008) · Patient Education and Counseling · doi:10.1016/j.pec.2008.05.006 · Cited by 152
Predictors of Remission After Electroconvulsive Therapy in Unipolar Major Depression
Dombrovski, A. Y., Mulsant, B. H., Haskett, R. F., Prudic, J., Begley, A. E., & Sackeïm, H. A. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0813 · Cited by 146
The Economic Burden of Treatment-Resistant Depression
Olchanski, N., McInnis Myers, M., Halseth, M., Cyr, P. L., Bockstedt, L., Goss, T. F., & Howland, R. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.001 · Cited by 146
Ivanova, J. I., Birnbaum, H. G., Kidolezi, Y., Subramanian, G., Khan, S., & Stensland, M. D. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.517716 · Cited by 143
Bareš, M., Brunovský, M., Kopeček, M., Novák, T., Stopková, P., Kožený, J., Šóš, P., Krajča, V., & Höschl, C. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.03.001 · Cited by 142
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140
Avery, D. H., Isenberg, K. E., Sampson, S. M., Janicak, P. G., Lisanby, S. H., Maixner, D. F., Loo, C., Thase, M. E., Demitrack, M. A., & George, M. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0315 · Cited by 129
Winner, J. G., Allen, J. D., Altar, C. A., & Mihajlovic, A. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.2 · Cited by 128
Self-citationEncyclopedia of Child Behavior and Development
Dade, P. (2011) · Reference Reviews · doi:10.1108/09504121111155932 · Cited by 101
Lamotrigine as an Augmentation Agent in Treatment-Resistant Depression
Barbee, J. G., & Jamhour, N. J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0813 · Cited by 98
Pukrop, R., Schlaak, V., Möller-Leimkühler, A. M., Albus, M., Czernik, A., Klosterkötter, J., & Möller, H. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00110-0 · Cited by 98
Altar, C. A., Hornberger, J. C., Shewade, A., Cruz, V., Garrison, J., & Mrazek, D. A. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.825579 · Cited by 97
Self-citationKocsis, J. H., Gelenberg, A. J., ROTHBAUM, B. O., Klein, D. N., Trivedi, M. H., Manber, R., Keller, M. B., Howland, R. H., & Thase, M. E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.01.002 · Cited by 97
Sava, F. A., Yates, B. T., Lupu, V., Szentágotai, A., & David, D. (2008) · Journal of Clinical Psychology · doi:10.1002/jclp.20550 · Cited by 96
Identifying Metabolic Risks With Antipsychotics and Monitoring and Management Strategies
Newcomer, J. W., & Sernyak, M. J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0707e17 · Cited by 93
Quetiapine augmentation of treatment-resistant depression: a comparison with lithium
Dorée, J.-P., Rosiers, J. D., Lew, V., Gendron, A., Elie, R., Stip, É., & Tourjman, V. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162809 · Cited by 90
Corey-Lisle, P. K., Birnbaum, H. G., Greenberg, P. E., Marynchenko, M. B., & Claxton, A. J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0810 · Cited by 84
Seidman, S. N., Miyazaki, M., & Roose, S. P. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000185424.23515.e5 · Cited by 75
Papakostas, G. I., Petersen, T., Pava, J. A., Masson, E., Worthington, J. J., Alpert, J. E., D, M. F. M., & Nierenberg, A. A. (2003) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000081591.46444.97 · Cited by 73
Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression
Inoue, T., Tsuchiya, K., Miura, J., Sakakibara, S., Denda, K., Kasahara, T., & Koyama, T. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00666-4 · Cited by 73
Fleury, M., Grenier, G., Bamvita, J., Perreault, M., Kestens, Y., & Caron, J. (2012) · International Journal for Equity in Health · doi:10.1186/1475-9276-11-20 · Cited by 73
Kopell, B. H., Halverson, J. L., Butson, C. R., Dickinson, M. D., Bobholz, J. A., Harsch, H. H., Rainey, C. J., Kondziolka, D. S., Howland, R. H., Eskandar, E. N., et al. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318229cfcd · Cited by 71
Schindler, F., & Anghelescu, I. G. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328014823d · Cited by 65
Somatic symptoms in treatment-resistant depression
Papakostas, G. I., Petersen, T., Denninger, J. W., Sonawalla, S. B., Mahal, Y., Alpert, J. E., Nierenberg, A. A., & D, M. F. M. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00063-5 · Cited by 64
Facilitating Clinical Implementation of Pharmacogenomics
Mrazek, D. A., & Lerman, C. E. (2011) · JAMA · doi:10.1001/jama.2011.1010 · Cited by 63
Self-citationMedicare patient experience with vagus nerve stimulation for treatment-resistant depression
Feldman, R. L., Dunner, D. L., Muller, J. S., & Stone, D. A. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.724745 · Cited by 61
Treatment-Resistant Depression Increases Health Costs and Resource Utilization
Lepine, B. A., Moreno, R. A., Campos, R. N., & Couttolenc, B. F. (2012) · Brazilian Journal of Psychiatry · doi:10.1016/j.rbp.2012.05.009 · Cited by 57
Treatment resistant depression and Axis I co-morbidity
PETERSEN, T., Gordon, J., Kant, A. J., D, M. F. M., Rosenbaum, J. F., & Nierenberg, A. A. (2001) · Psychological Medicine · doi:10.1017/s0033291701004305 · Cited by 57
Genetics and Variable Drug Response
Wilke, R. A., & Dolan, M. E. (2011) · JAMA · doi:10.1001/jama.2011.998 · Cited by 56
Swan, J., Sorrell, E., MacVicar, B., Durham, R., & Matthews, K. (2003) · Journal of Affective Disorders · doi:10.1016/j.jad.2003.09.002 · Cited by 49
Aziz, M., Mehringer, A. M., Mozurkewich, E., & Razik, G. N. (2005) · PubMed · Cited by 42
Karp, J. F., Whyte, E. M., Lenze, E. J., Dew, M. A., Begley, A. E., Miller, M. D., & Reynolds, C. F. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0317 · Cited by 39
Papakostas, G. I., Petersen, T., Farabaugh, A. H., Murakami, J. L., Pava, J. A., Alpert, J. E., D, M. F. M., & Nierenberg, A. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1112 · Cited by 33
Dumas, R., Richieri, R. M., Guedj, É., Auquier, P., Lançon, C., & Boyer, L. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-87 · Cited by 33
Benedict, Á., Arellano, J., Cock, E. D., & Baird, J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.04.017 · Cited by 28
Assessment of Clinical Guidelines for Continuation Treatment in Major Depression
Nuijten, M. J. C. (2001) · Value in Health · doi:10.1046/j.1524-4733.2001.44053.x · Cited by 23
Lenox‐Smith, A., Greenstreet, L., Burslem, K., & Knight, C. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929030-00004 · Cited by 16
Oral d-fenfluramine test in treatment-refractory depression
Prochazka, H., Sjögren, M. J. C., & Ågren, H. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00094-4 · Cited by 13
Taneja, C., Papakostas, G. I., Jing, Y., Baker, R. A., Forbes, R. A., & Oster, G. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q326 · Cited by 13
Santé mentale et déterminants sociaux
Pierre, S. (2010) · L Encéphale · doi:10.1016/s0013-7006(10)70015-4 · Cited by 9
Naturalistic study of the early psychiatric use of citalopram in the United States
Rush, A. J., Bose, A., & Heydorn, W. E. (2002) · Depression and Anxiety · doi:10.1002/da.10056 · Cited by 7
Research works printed but not linked: 3
- Nierenberg AA, 2001, Journal of Clinical Psychiatry, 62, 5
- Thase ME, 1997, Journal of Clinical Psychiatry, 58, 23
- 1976, Clinical Global Impression (CGI)
Cited by
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Twenge, J. M., Cooper, A. B., Joiner, T. E., Duffy, M. E., & Binau, S. G. (2019) · Journal of Abnormal Psychology · doi:10.1037/abn0000410 · Cited by 1,469
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02400-6 · Cited by 520
“Although there are available antidepressants, most of the pharmacologic interventions take weeks to months to produce effects and have low response rates [3, 4].”
BackgroundZhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., & Sheehan, J. J. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13699 · Cited by 523
Gordon, B. R., McDowell, C. P., Hallgren, M., Meyer, J. D., Lyons, M., & Herring, M. P. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0572 · Cited by 498
Metadata
- Authors
- Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I.
- Affiliations
- Mayo Clinic (US)
- Venue
- Psychiatric Services
- Published
- 2014-08
- Volume
- 65
- Issue
- 8
- Pages
- 977-987
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2111118992
- Cited by
- 580
- References
- 80
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 37 · 2023: 76 · 2022: 62 · 2021: 78 · 2020: 64 · 2019: 66 · 2018: 49 · 2017: 28 · 2016: 23 · 2015: 19 · 2014: 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, economic burden, social burden, quality of life, health care costs, productivity loss, treatment response rate, suicide attempts, disease duration, major depressive disorder
- MeSH terms
- Major Depressive Disorder, Depressive Disorder, Major, Humans, Quality of Life, Cost of Illness, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.